[go: up one dir, main page]

PE20020307A1 - Forma de dosificacion de farmaco activada por hidrogel - Google Patents

Forma de dosificacion de farmaco activada por hidrogel

Info

Publication number
PE20020307A1
PE20020307A1 PE2001000791A PE2001000791A PE20020307A1 PE 20020307 A1 PE20020307 A1 PE 20020307A1 PE 2001000791 A PE2001000791 A PE 2001000791A PE 2001000791 A PE2001000791 A PE 2001000791A PE 20020307 A1 PE20020307 A1 PE 20020307A1
Authority
PE
Peru
Prior art keywords
compositions
hydrogel
dosage form
drug dosage
drug
Prior art date
Application number
PE2001000791A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Walter C Babcock
Ronald Arthur Beyerinck
Mark Brian Chidlaw
William John Curatolo
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20020307A1 publication Critical patent/PE20020307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN DISPOSITIVO DE SUMINISTRO DE FARMACO, QUE COMPRENDE: a) UN NUCLEO QUE CONTIENE DOS COMPOSICIONES DE FARMACO DIFERENTES UNA DE OTRA Y UNA COMPOSICION HINCHABLE CON AGUA, OCUPANDO CADA UNA DE LAS COMPOSICIONES REGIONES SEPARADAS; ESTANDO LA ULTIMA DE ELLAS LOCALIZADA ENTRE LAS DOS COMPOSICIONES DE FARMACO; Y, b) UN RECUBRIMIENTO ALREDEDOR DE (a), PERMEABLE E INSOLUBLE AL AGUA, QUE TIENE AL MENOS UNA ABERTURA DE SUMINISTRO PARA COMUNICACION CON LAS COMPOSICIONES DE FARMACO. COMPRENDIENDO UNA DE LAS COMPOSICIONES UN FARMACO DE BAJA SOLUBILIDAD Y LA OTRA COMPOSICION UN AGENTE DE ARRASTRE DEL FARMACO
PE2001000791A 2000-08-09 2001-08-08 Forma de dosificacion de farmaco activada por hidrogel PE20020307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
PE20020307A1 true PE20020307A1 (es) 2002-04-23

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000791A PE20020307A1 (es) 2000-08-09 2001-08-08 Forma de dosificacion de farmaco activada por hidrogel

Country Status (30)

Country Link
US (2) US20030086972A1 (es)
EP (1) EP1326587A2 (es)
JP (1) JP2004505907A (es)
KR (1) KR20030024844A (es)
CN (1) CN1461212A (es)
AP (1) AP2001002237A0 (es)
AU (1) AU2002229141A1 (es)
BG (1) BG107538A (es)
BR (1) BR0113067A (es)
CA (1) CA2418907A1 (es)
DO (1) DOP2001000229A (es)
EA (1) EA200300081A1 (es)
EC (1) ECSP034455A (es)
EE (1) EE200300055A (es)
GT (1) GT200100161A (es)
HR (1) HRP20030082A2 (es)
HU (1) HUP0300722A2 (es)
IL (1) IL154012A0 (es)
IS (1) IS6686A (es)
MA (1) MA26939A1 (es)
MX (1) MXPA03001209A (es)
NO (1) NO20030627L (es)
OA (1) OA12365A (es)
PA (1) PA8524901A1 (es)
PE (1) PE20020307A1 (es)
PL (1) PL360658A1 (es)
SV (1) SV2002000586A (es)
TN (1) TNSN01123A1 (es)
UY (1) UY26876A1 (es)
WO (1) WO2002011702A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
MXPA04002992A (es) 2001-09-28 2005-06-20 Johnson & Johnson Composicion comestible y forma de dosificacion que comprende una cubierta comestible.
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
NZ538842A (en) * 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
JP2013510135A (ja) * 2009-11-09 2013-03-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 送達担体
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
ES2725879T3 (es) * 2013-01-30 2019-09-30 Daewoong Co Ltd Composición farmacéutica para la protección de heridas, para proporcionar una hemostasia o para evitar la adhesión en el tracto gastrointestinal
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CA3088017A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
EP4346762A1 (en) * 2021-05-28 2024-04-10 Amgen Inc. Formulations of apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
JPWO2023063381A1 (es) * 2021-10-14 2023-04-20

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
SI9520049A (en) * 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
PL337804A1 (en) * 1997-07-01 2000-09-11 Pfizer Prod Inc Solubilised compositions of sertralin
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2346335C (en) * 1998-10-13 2006-04-18 Pfizer Products Inc. Sertraline oral concentrate
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GT200100039A (es) * 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
PL377479A1 (pl) * 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Also Published As

Publication number Publication date
HUP0300722A2 (hu) 2003-11-28
PA8524901A1 (es) 2002-04-25
AP2001002237A0 (en) 2001-09-30
SV2002000586A (es) 2002-10-24
PL360658A1 (en) 2004-09-20
ECSP034455A (es) 2003-03-10
WO2002011702A3 (en) 2002-11-28
US20030086972A1 (en) 2003-05-08
NO20030627L (no) 2003-04-08
EA200300081A1 (ru) 2003-08-28
EP1326587A2 (en) 2003-07-16
DOP2001000229A (es) 2002-09-30
BR0113067A (pt) 2003-07-01
US20040052845A1 (en) 2004-03-18
AU2002229141A1 (en) 2002-02-18
HRP20030082A2 (en) 2003-04-30
TNSN01123A1 (fr) 2005-11-10
CN1461212A (zh) 2003-12-10
BG107538A (bg) 2003-11-28
OA12365A (en) 2006-05-16
IL154012A0 (en) 2003-07-31
CA2418907A1 (en) 2002-02-14
GT200100161A (es) 2002-03-22
JP2004505907A (ja) 2004-02-26
IS6686A (is) 2003-01-16
NO20030627D0 (no) 2003-02-07
MA26939A1 (fr) 2004-12-20
UY26876A1 (es) 2002-03-22
WO2002011702A2 (en) 2002-02-14
MXPA03001209A (es) 2003-06-30
EE200300055A (et) 2004-12-15
KR20030024844A (ko) 2003-03-26

Similar Documents

Publication Publication Date Title
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
ES2097787T3 (es) Composicion farmaceutica para la administracion rectal de principios activos que presenta una accion de medicacion prevalentemente topica a nivel del colon.
AR019690A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
SV2002000969A (es) Composicion parenteral reconstituible
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
UY25544A1 (es) Forma de dosificación de nefazodona
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR010716A1 (es) Formulacion para tabletas efervecentes desinfectantes y metodo para formar una solucion desinfectante
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
BR0314787A (pt) Forma de dosagem de liberação modificada
AR037131A1 (es) Formulaciones de jarabe de ribavirina
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
ECSP003685A (es) Formulaciones orales de liberacion controlada

Legal Events

Date Code Title Description
FD Application declared void or lapsed